Angioflux

Sulodexide

Angioflux

Principio attivo

Sulodexide

Dosaggio e forma farmaceutica

250 ULS capsule molli - 50 capsule molli
600 ULS/2 ml soluzione iniettabile - 10 fiale

ATC

B01AB11 - Antitrombotici/Eparinici

Indicazioni terapeutiche

Ulcere venose croniche

Titolare AIC

Aesculapius Farmaceutici S.r.l.

Classificazione ai fini della fornitura

Medicinale soggetto a prescrizione medica

Regime di rimborsabilità

Classe C

Prezzo

250 ULS capsule molli – 50 capsule 30,00 €
600 ULS/2 ml soluzione iniettabile – 10 fiale 21,00 €

Download area

Riassunto caratteristiche del prodotto - Angioflux

Efficacy of sulodexide as adjunct in trabeculectomy. A two-year randomized clinical study (Acta Ophtalmologica Scandinavica, 2000)

The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (Vascular Medicine, 2009)

Use of sulodexide in patients with peripheral vascular disease (Journal of Blood Medicine, 2010)

A new mechanism of action of sulodexide in diabetic nephropathy inhibits heparanase-1 and prevents FGF-2-induced renal epithelialmesenchymal transition (Journal of Translational Medicine, 2012)

Sulodexide, an old drug with recent renewed interest (2013)

Sulodexide Review of recent clinical efficacy data (2013)

Effect of Sulodexide on Urinary Biomarkers of Kidney Injury in Normoalbuminuric Type 2 Diabetes A Randomized Controlled Trial (Hindawi Publishing Corporation Journal of Diabetes Research, 2015)

Depositato presso AIFA in data: 16/05/2019
AEWEB2019

Eventi

06-07/12/2019

XVI CONGR NAZ FLEBOFORUM- XIV SIMPOSIO MALATTIA VARICOSA- VII FLEB WINTER FARM

NAPOLI

XVI CONGR NAZ FLEBOFORUM- XIV SIMPOSIO MALATTIA VARICOSA- VII FLEB WINTER FARM

 Download

08-10/11/2019

XXXII CONGRESSO NAZIONALE SNaMID

CATANIA

XXXII CONGRESSO NAZIONALE SNaMID